EnGene
Biotechnology firm focused on developing treatments for mucosal diseases by inducing therapeutic proteins to counter harmful agents.
Employees
Enterprise value
$67m
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 Valuation: €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | $60.0m | Private Placement VC | |
| Total Funding | 000k | ||
RBC Capital Markets(exited)
Kodiak Venture Partners(exited)
Lumira Ventures(exited)
Fonds de solidarité FTQ(exited)
Pharmstandard(exited)
Inbio Ventures(exited)
Cystic Fibrosis Foundation(exited)
Forbion Capital Partners(exited)
Venrock(exited)
Deep Track Capital(exited)
Commodore Capital(exited)
Adage Capital(exited)
Logos Capital(exited)
Marshall Wace(exited)
CTI Life Sciences(exited)
Vivo Capital(exited)
Northleaf(exited)
Cowen Group(exited)
Boxer Capital(exited)
Invest Quebec(exited)
Surveyor Capital(exited)
Janus Henderson Investors(exited)
Perceptive Advisors(exited)
BVF Partners(exited)
Cormorant Asset Management(exited)
Soleus Capital(exited)
Omega Funds(exited)
Blue Owl Capital(exited)
Foresite Capital(exited)
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.